Search research articles
Contact Us
Filters
Showing results (91-100 of 102) with videos related to
Page
of 11
Sort By:
Nature Communications
|
July 6, 2023
Detecting temporal and spatial malaria patterns from first antenatal care visits
Arnau Pujol, Nanna Brokhattingen, Glória Matambisso, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 6, 2018
Identifying Immune Correlates of Protection Against Plasmodium falciparum Through a Novel Approach to Account for Heterogeneity in Malaria Exposure
Aida Valmaseda, Eusebio Macete, Augusto Nhabomba, et al.
Communications Biology
|
June 8, 2023
Targeted and whole-genome sequencing reveal a north-south divide in P. falciparum drug resistance markers and genetic structure in Mozambique
Clemente da Silva, Simone Boene, Debayan Datta, et al.
BMC Medicine
|
November 1, 2018
Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children
Itziar Ubillos, Aintzane Ayestaran, Augusto J Nhabomba, et al.
Elife
|
June 26, 2026
Estimating probabilities of malaria importation in southern Mozambique through modelling <i>P. falciparum</i> genomics and mobility patterns
Arnau Pujol, Arlindo Chidimatembue, Clemente da Silva, et al.
Scientific Reports
|
August 11, 2025
Antimalarial drug resistance and population structure of Plasmodium falciparum in Mozambique using genomic surveillance at health facilities in 2021 and 2022
Simone Boene, Eduard Rovira-Vallbona, Clemente da Silva, et al.
Vaccine
|
November 12, 2019
Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa
Lucas Otieno, Yolanda Guerra Mendoza, Samuel Adjei, et al.
The Lancet. Infectious Diseases
|
September 7, 2015
Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial
Michael T White, Robert Verity, Jamie T Griffin, et al.
Human Vaccines & Immunotherapeutics
|
April 24, 2019
Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa
Yolanda Guerra Mendoza, Elodie Garric, Amanda Leach, et al.
The New England Journal of Medicine
|
October 20, 2011
First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children
, Selidji Todagbe Agnandji, Bertrand Lell, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 102) with videos related to
Sort By:
Page
of 11
Nature Communications
|
July 6, 2023
Detecting temporal and spatial malaria patterns from first antenatal care visits
Arnau Pujol, Nanna Brokhattingen, Glória Matambisso, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 6, 2018
Identifying Immune Correlates of Protection Against Plasmodium falciparum Through a Novel Approach to Account for Heterogeneity in Malaria Exposure
Aida Valmaseda, Eusebio Macete, Augusto Nhabomba, et al.
Communications Biology
|
June 8, 2023
Targeted and whole-genome sequencing reveal a north-south divide in P. falciparum drug resistance markers and genetic structure in Mozambique
Clemente da Silva, Simone Boene, Debayan Datta, et al.
BMC Medicine
|
November 1, 2018
Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children
Itziar Ubillos, Aintzane Ayestaran, Augusto J Nhabomba, et al.
Elife
|
June 26, 2026
Estimating probabilities of malaria importation in southern Mozambique through modelling <i>P. falciparum</i> genomics and mobility patterns
Arnau Pujol, Arlindo Chidimatembue, Clemente da Silva, et al.
Scientific Reports
|
August 11, 2025
Antimalarial drug resistance and population structure of Plasmodium falciparum in Mozambique using genomic surveillance at health facilities in 2021 and 2022
Simone Boene, Eduard Rovira-Vallbona, Clemente da Silva, et al.
Vaccine
|
November 12, 2019
Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa
Lucas Otieno, Yolanda Guerra Mendoza, Samuel Adjei, et al.
The Lancet. Infectious Diseases
|
September 7, 2015
Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial
Michael T White, Robert Verity, Jamie T Griffin, et al.
Human Vaccines & Immunotherapeutics
|
April 24, 2019
Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa
Yolanda Guerra Mendoza, Elodie Garric, Amanda Leach, et al.
The New England Journal of Medicine
|
October 20, 2011
First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children
, Selidji Todagbe Agnandji, Bertrand Lell, et al.
Page
of 11